Publication
A 2018 Overview of Diuretic Resistance in Heart Failure
| dc.contributor.author | Jardim, SI | |
| dc.contributor.author | Ramos dos Santos, L | |
| dc.contributor.author | Araújo, I | |
| dc.contributor.author | Marques, F | |
| dc.contributor.author | Branco, P | |
| dc.contributor.author | Gaspar, A | |
| dc.contributor.author | Fonseca, C | |
| dc.date.accessioned | 2019-08-06T15:17:08Z | |
| dc.date.available | 2019-08-06T15:17:08Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Heart failure is a disease with high direct and indirect costs. Current treatment includes drugs that alter disease progression and drugs that to improve symptoms. Loop diuretics are the cornerstone of congestion relief for acute management, as well as for chronic stabilization. In heart failure patients, maximal diuretic response is reduced by many individual factors. Diuretic resistance is defined as failure to achieve effective congestion relief despite appropriate or escalating diuretic doses. Its causes include impaired delivery of the diuretic to its luminal site of action, neurohormonal activation, tubular compensatory adaptation and drug interactions. Several strategies can be employed to aid decongestion of patients with impaired diuretic response. These include salt restriction, a higher effective single dose or higher dose frequency of loop diuretics, continuous infusion of diuretics and/or sequential nephron blockade through a synergistic combination of two or more diuretics from different classes. Ultrafiltration has also been found to be another effective and safe therapeutic option and should be considered in patients with refractory diuretic resistance. Overall, there is a lack of high-quality clinical data to guide the choice of treatment strategy and therapy should be tailored on a case-by-case basis. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Rev Port Cardiol. 2018 Nov;37(11):935-945. | pt_PT |
| dc.identifier.doi | 10.1016/j.repc.2018.03.014 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/3281 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.subject | HSJ MED | pt_PT |
| dc.subject | Diuretics/adverse effects | pt_PT |
| dc.subject | Diuretics/therapeutic use | pt_PT |
| dc.subject | Drug Resistance | pt_PT |
| dc.subject | Heart Failure/drug therapy | |
| dc.subject | Heart Failure/physiopathology | |
| dc.title | A 2018 Overview of Diuretic Resistance in Heart Failure | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 945 | pt_PT |
| oaire.citation.issue | 11 | pt_PT |
| oaire.citation.startPage | 935 | pt_PT |
| oaire.citation.title | Revista Portuguesa de Cardiologia | pt_PT |
| oaire.citation.volume | 37 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |